Glenmark launches world's first nebulized triple therapy for COPD

Glenmark Pharmaceuticals Ltd. announced on November 25, 2025, the launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world's first nebulized, fixed-dose triple therapy for chronic obstructive pulmonary disease (COPD). This innovative treatment combines Glycopyrronium, Formoterol, and Budesonide to alleviate airway obstruction, inflammation, and enhance lung function and symptom control.

The introduction of these products represents a global first, offering a simpler and more effective alternative for COPD patients, particularly those who face challenges using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI). A clinical study in India demonstrated the therapy's rapid improvement in lung function, better control of breathlessness, and a favorable safety profile.

This launch reinforces Glenmark's leadership in respiratory innovation and its commitment to providing advanced and accessible solutions for patients worldwide. The company, a research-led global pharmaceutical firm, operates across branded, generics, and OTC segments, with 11 manufacturing facilities and operations in over 80 countries.